Vitro Biopharma is an innovative biotechnology company based in Golden, CO, dedicated to developing Wharton's jelly-derived cell therapies for autoimmune diseases and inflammatory disorders. With a focus on translating science into transformative medicines, their goal is to become a leader in the immunology and inflammatory market by developing differentiated product candidates in a rapid and efficient manner.
With over 30 years of research and expertise, Vitro Biopharma leverages the biological advantages of UC-derived MSCs (mesenchymal stem cells) and follows strict environmental and laboratory controls in their cGMP-compliant manufacturing process. Their scalable and standardized manufacturing approach, combined with their commitment to quality and compliance, positions them to have a significant cost and competitive advantage over their peers in the biologics industry.
Generated from the website